In a research paper published in PLOS ONE, Dario C. Altieri, president and chief executive officer, director of the Ellen and Ronald Caplan Cancer Center, and the Robert and Penny Fox Distinguished Professor at The Wistar Institute, alongside national and international collaborators, distinguish a specific gene signature indicative of mitochondrial reprogramming in tumors that correlates with poor patient outcome.
The PERLA phase II trial met its primary endpoint of objective response rate by Response Evaluation Criteria in Solid Tumors criteria as determined by blinded independent central review. The trial evaluated Jemperli (dostarlimab) in combination with chemotherapy versus pembrolizumab in combination with chemotherapy in first-line patients with metastatic non-squamous NSCLC.
Researchers at UNC Lineberger Comprehensive Cancer Center have found a possible way to overcome barriers that block effective anti-cancer immune responses, thereby opening the potential for more effective immunotherapies in people.
A collaborative effort between investigators at Roswell Park Comprehensive Cancer Center and the Center for Molecular Immunology in Havana, Cuba, has revealed a new strategy for correcting immune dysfunction in cancer patients.
A new study—published this week in Science Advances—uncovered a previously unknown genetic process that could inform the development of novel treatment options for glioblastoma.
The findings from the 2022 National Youth Tobacco Survey on e-cigarette use among U.S. youth, published by FDA and CDC in Morbidity & Mortality Weekly Report, show that youth use of e-cigarettes remains high, with 2.5 million (9.4%) of the nation’s middle and high school students reporting current e-cigarette use.
Researchers at Baylor College of Medicine found that a key genetic variant risk factor, PNPLA3, plays a synergistic role in increasing the risk for cirrhosis, liver cancer, and liver-related death when combined with alcohol use and obesity.
A clinical trial led by clinicians at Georgetown Lombardi Comprehensive Cancer Center showed a remarkable 20% advantage in the two-year OS rate for people with advanced melanoma who first received immunotherapy (72% survival rate) versus those who initially got targeted therapies (52% survival rate). Progression-free survival, where the cancer is stable or improving, was also trending in favor of those who started on immunotherapy.
A new class of small molecule drugs, now in phase I clinical trials, is the first to target circadian clock proteins, which play a key role in the recurrence and spread of glioblastoma.
University of Minnesota Medical School researchers explored the possible biological mechanisms that could explain the association between being overweight or obese prior to pregnancy and the increased risk of acute lymphoblastic leukemia in children.
